POSA282 Oncology Drugs without Phase III Data: Comparison of Reimbursement Recommendations Issued by the Canadian Agency for Drugs and Technologies in Health (CADTH), and the National Institute for Health and Care Excellence (NICE)
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.849
https://www.valueinhealthjournal.com/article/S1098-3015(21)02644-9/fulltext
Title :
POSA282 Oncology Drugs without Phase III Data: Comparison of Reimbursement Recommendations Issued by the Canadian Agency for Drugs and Technologies in Health (CADTH), and the National Institute for Health and Care Excellence (NICE)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02644-9&doi=10.1016/j.jval.2021.11.849
First page :
Section Title :
Open access? :
No
Section Order :
10373